Universe Pharmaceuticals (UPC)
NASDAQ:UPC
Top Page
Universe Pharmaceuticals
(NASDAQ:UPC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.00
▼(-28.91% Downside)
Action:ReiteratedDate:02/14/26
The score is primarily held back by weak financial performance (multi-year revenue decline, ongoing losses, and negative operating/free cash flow). Technicals also weigh on the rating due to a clear downtrend and negative momentum indicators. Valuation is mixed: a negative P/E reflects loss-making operations and no dividend yield is available, though the balance sheet’s low leverage provides some support.
Positive Factors
Conservative leverage and manageable debt
Low absolute debt and a ~0.16 debt-to-equity ratio provide financial flexibility and lower near-term refinancing risk. This balance-sheet conservatism gives the company runway to pursue margin recovery or restructuring without immediate solvency pressure, supporting stability over coming months.
Negative Factors
Multi-year revenue decline and shrinking scale
A prolonged drop in revenue erodes fixed-cost absorption, distribution bargaining power, and R&D/marketing capacity. Shrinking scale makes it harder to translate margin improvements into overall profitability and undermines long-term competitive position absent a clear and sustained rebound.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage and manageable debt
Low absolute debt and a ~0.16 debt-to-equity ratio provide financial flexibility and lower near-term refinancing risk. This balance-sheet conservatism gives the company runway to pursue margin recovery or restructuring without immediate solvency pressure, supporting stability over coming months.
Read all positive factors
Universe Pharmaceuticals (UPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.78M
Dividend YieldN/A
Average Volume (3M)955.25K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue Growth-27.81%
EPS GrowthN/A
CountryUS
Employees225
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding563,338
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-12.67
Enterprise Value/Revenue-1.26
Enterprise Value/Gross Profit-3.58
Enterprise Value/Ebitda7.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Universe Pharmaceuticals Business Overview & Revenue Model
Company Description
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health condi...
How the Company Makes Money
null...
Universe Pharmaceuticals Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.86M | 23.02M | 32.31M | 40.14M | 47.98M |
| Gross Profit | 6.30M | 6.07M | 10.32M | 21.89M | 25.33M |
| EBITDA | -2.92M | -7.36M | -3.18M | -6.40M | 14.20M |
| Net Income | -3.67M | -8.73M | -6.16M | -8.74M | 11.32M |
Balance Sheet | |||||
| Total Assets | 69.30M | 67.95M | 53.29M | 59.54M | 70.14M |
| Cash, Cash Equivalents and Short-Term Investments | 33.59M | 29.50M | 18.50M | 18.86M | 21.80M |
| Total Debt | 9.26M | 7.99M | 5.48M | 3.94M | 4.33M |
| Total Liabilities | 13.17M | 22.45M | 13.75M | 13.10M | 11.21M |
| Stockholders Equity | 56.13M | 45.50M | 39.53M | 46.44M | 58.93M |
Cash Flow | |||||
| Free Cash Flow | -5.40M | -9.87M | 1.08M | -1.41M | -15.59M |
| Operating Cash Flow | -5.05M | -9.51M | 1.12M | -1.31M | -2.06M |
| Investing Cash Flow | -341.81K | -361.29K | -44.17K | -3.91M | -27.06M |
| Financing Cash Flow | 9.73M | 33.95M | -1.39M | 3.32M | 26.58M |
Universe Pharmaceuticals Technical Analysis
Positive
4.22
Price Trends
3.11
Positive
3.54
Negative
3.87
Negative
Market Momentum
-0.06
Negative
62.23
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPC, the sentiment is Positive. The current price of 4.22 is above the 20-day moving average (MA) of 2.56, above the 50-day MA of 3.11, and above the 200-day MA of 3.87, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 62.23 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UPC.
Universe Pharmaceuticals Risk Analysis
Universe Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Universe Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Universe Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $4.07M | -0.42 | ― | ― | ― | ― | |
46 Neutral | $1.78M | >-0.01 | 2.66% | ― | -27.81% | ― | |
45 Neutral | $3.16M | ― | -43.00% | ― | -26.92% | 69.90% | |
42 Neutral | $1.77M | -0.43 | ― | ― | ― | ― | |
| ― | $4.24M | -0.25 | -9999.00% | ― | ― | 79.31% |
* Healthcare Sector Average
UPC
Universe Pharmaceuticals
3.16
0.07
2.27%
CPHI
China Pharma Holdings
0.63
-0.67
-51.54%
RDHL
RedHill Biopharma
0.80
-1.25
-61.02%
SXTC
China SXT Pharmaceuticals
1.89
-389.61
-99.52%
PRFX
PainReform
2.10
-7.50
-78.12%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.76
-10.30
-93.14%
Universe Pharmaceuticals Corporate Events
Universe Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share Structure
Feb 11, 2026
Universe Pharmaceuticals INC, a Ji’an-based producer and distributor of traditional Chinese medicine derivatives and other pharmaceutical products across 30 Chinese provinces, has detailed its business focus on elderly patients’ health...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.